Synthetic peptides are lawful to make, sell and buy in the United States as laboratory reagents. They are not lawful to sell for use in a person: none of the compounds discussed here is an FDA-approved drug, and under 21 U.S.C. 355(a) an unapproved new drug may not be introduced into interstate commerce. Almost no peptide is a controlled substance, so "are peptides legal" is a food-and-drug question rather than a drug-enforcement one, and the anti-doping rules that ban many of them in sport are a third thing again.
This post is not legal advice. It is a plain description of the federal rules that apply, with every citation opened and checked, so that a buyer can see which rule governs which question.
"Legal" depends on what the material is for
US drug law turns on intended use, not on chemistry. The same sequence can be a reagent in one context and an unapproved drug in another, and what decides the difference is the purpose the seller shows: the labeling, the advertising, the surrounding statements, and the circumstances of distribution. The post on research peptides and what "research use only" means traces that rule through FDA's regulation on intended use and the labeling rule the phrase comes from.
Two consequences run through everything below. A supplier that sells a characterized reagent for laboratory work is selling a reagent; a supplier that sells the same vial with claims about what it does in a person, amounts for a person, or anything packaged for self-use is offering an unapproved drug, whatever the label says. And the buyer's own use is a separate question from the seller's offer: nothing in a research-use statement makes use in a person lawful.
Anhydrolabs supplies each compound as a lyophilized powder in a vacuum-sealed vial and as 10-vial kits, with identity and lot data on the product page. The research-use statement sets out the wording the company stands behind.
They are not approved drugs
An approved drug is a specific product, from a specific manufacturer, for a specific labeled use, backed by an application FDA has reviewed. 21 U.S.C. 355(a) is the gate: no new drug may be introduced or delivered for introduction into interstate commerce unless an approval is in effect for it.
A handful of peptide sequences have been through that gate as finished drug products under particular brand names and manufacturers. Most of the sequences sold as research reagents have not — BPC-157, TB-500, KPV, MOTS-c, epitalon, selank, semax, GHK-Cu and the growth hormone secretagogues among them. For those there is no approved product, no approved labeled use, and no lawful way to offer them for use in a person in the United States. The primer on GLP-1 receptor agonists shows how sharply an approved product and a research reagent of the same sequence diverge in what may be said about them.
"Not approved" is a status, not a verdict on the science. It means FDA has reviewed no application for that product, so no representation about safety or effectiveness in a person can rest on an FDA finding.
FDA's position on compounded and bulk peptide substances
The adjacent question people run into is compounding. A compounder working under section 503A of the FD&C Act may only use a bulk drug substance that complies with a USP or NF monograph, is a component of an FDA-approved drug, or appears on a list FDA establishes by rulemaking. That list is codified at 21 CFR 216.23, and it is short: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide. No peptide is on it.
While that list is built, FDA sorts nominated substances into interim categories. Category 2 holds substances FDA says may present significant safety risks. FDA's Category 2 page, last updated April 22, 2026, carries two tables that matter here.
| Peptide | Where it sits in FDA's compounding lists |
|---|---|
| GHRP-2, GHRP-6, ipamorelin acetate | Category 2 for outsourcing facilities (503B), added September 29, 2023 |
| Kisspeptin-10 | Category 2 for 503A compounding, added September 29, 2023 |
| BPC-157, TB-500, KPV, MOTS-c, semax, epitalon, emideltide (DSIP) | Nominated, then withdrawn by the nominator; listed on FDA's withdrawn table |
| AOD-9604, CJC-1295, GHK-Cu (injectable routes), cathelicidin LL-37, melanotan II, PEG-MGF, selank acetate, thymosin alpha-1, dihexa acetate | Nominated, then withdrawn by the nominator |
FDA's stated concerns for the peptides in Category 2 are consistent: risk of immunogenicity for certain routes of administration, difficulty characterizing peptide-related impurities, unnatural amino acids that complicate characterization, and in several cases no safety information at all for the proposed routes.
Coming off the withdrawn table is not the same as being cleared. A substance is usable in 503A compounding only if it meets one of the three statutory conditions, and the list at 21 CFR 216.23 is changed by rulemaking. On April 16, 2026, FDA published a Federal Register notice (Docket No. FDA-2025-N-6895) announcing a two-day advisory committee meeting on whether seven peptides should go on that list: BPC-157, KPV, TB-500 and MOTS-c on July 23, 2026, and emideltide (DSIP), semax and epitalon on July 24, 2026. The notice names the uses FDA evaluated for each, from ulcerative colitis for BPC-157 to insomnia for epitalon.
A committee recommendation is advice, not a rule. As of this writing, 21 CFR 216.23 still lists the same six non-peptide substances. None of this bears directly on a reagent sale; it matters because it is the clearest published statement of what FDA thinks about these molecules as drug substances, and because it is the part of the picture that changes most often.
Which peptides are actually controlled substances
Very few, and probably none that a research buyer will encounter.
The Controlled Substances Act schedules are in 21 CFR Part 1308, and DEA publishes the current list in alphabetical order. No entry on it corresponds to BPC-157, TB-500, KPV, MOTS-c, semax, selank, epitalon, GHK-Cu, kisspeptin, ipamorelin, sermorelin, tesamorelin, CJC-1295, melanotan II, semaglutide, tirzepatide, retatrutide or growth hormone itself. Peptides are not scheduled as a class.
Two near neighbors cause most of the confusion.
Anabolic steroids are Schedule III. They are steroids — small lipid molecules built on a four-ring carbon skeleton — not peptides. A peptide does not become a controlled substance by being studied in a similar context.
Human growth hormone has its own federal offense, outside the schedules. 21 U.S.C. 333(e) makes it a crime to knowingly distribute, or possess with intent to distribute, human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition, where that use is authorized by the Secretary and ordered by a physician. The penalty is up to five years, and up to ten where a person under 18 is involved. The statute defines human growth hormone as somatrem, somatropin, or an analogue of either. That is a narrow definition: it reaches growth hormone itself and its analogues, not the short secretagogue peptides that act upstream of it.
So the honest answer to "are peptides controlled substances" is no, with one carve-out for growth hormone that is a Food, Drug, and Cosmetic Act offense rather than a scheduling one.
Import and customs
Imported drugs are handled under 21 U.S.C. 381(a). FDA may refuse admission to an article that appears to be adulterated, misbranded, or in violation of section 355 — that last phrase covering unapproved new drugs. A refused article must be exported or destroyed within 90 days of the refusal notice, and drugs valued at $2,500 or less may be destroyed after notice and an opportunity to respond, without an export option.
Customs and Border Protection examines parcels and refers FDA-regulated articles; FDA then decides admissibility. FDA also maintains import alerts that authorize detention without physical examination of unapproved new drugs promoted in the US, which is why a shipment can be held on the strength of the seller's marketing rather than the contents of the vial.
There is a discretionary personal-importation policy, set out in FDA's Regulatory Procedures Manual, Chapter 9, and it is narrower than its reputation. Its factors include that the product is not commercialized or promoted to people in the US, that it is not an unreasonable risk, and that the individual affirms in writing that it is for their own use and names a US physician responsible for their treatment with it. A peptide bought from a website that markets to US buyers does not fit those factors.
For a laboratory, the practical point is documentation that matches the goods. A shipment described accurately as a research reagent, with a certificate of analysis behind it, is a different proposition from one whose seller's own site frames it as something to put in a body. The post on how to read a peptide certificate of analysis covers what that paperwork should contain.
Anti-doping is a separate question
Nothing on the World Anti-Doping Agency's Prohibited List is a matter of US law. The List binds people subject to an anti-doping program through their sport, and a violation carries a sporting sanction. A substance can be entirely lawful to possess and still be prohibited in competition — and most research peptides are.
The 2026 List came into effect on 1 January 2026. Its reach over peptides is wide and deliberately open-ended.
| Section | What it covers | Peptides named on the 2026 List |
|---|---|---|
| S0 Non-approved substances | Any pharmacological substance not addressed elsewhere on the List and with no current approval by any government regulator for use in people | BPC-157 (named explicitly) |
| S2.2.1 Testosterone-stimulating peptides in males | Gonadotrophins and releasing factors | Chorionic gonadotrophin, luteinizing hormone, GnRH and its agonist analogues, kisspeptin and its agonist analogues |
| S2.2.3 Growth hormone, analogues and fragments | GH itself and fragments of it | Lonapegsomatropin, somapacitan, somatrogon, AOD-9604, hGH 176-191 |
| S2.2.4 Growth hormone releasing factors | GHRH analogues, secretagogues and GHRPs | CJC-1293, CJC-1295, sermorelin, tesamorelin, anamorelin, ibutamoren (MK-677), ipamorelin, macimorelin, hexarelin, GHRP-1 through GHRP-6 |
| S2.3 Growth factors and modulators | Factors affecting muscle, tendon or ligament protein synthesis, vascularisation and fibre type | IGF-1 (mecasermin) and its analogues, mechano growth factors, thymosin-β4 and derivatives such as TB-500, VEGF, PDGF, FGFs, HGF |
| S4.4.1 Metabolic modulators | AMPK activators | AICAR, MOTS-c |
Everything in S2 is prohibited at all times, in and out of competition, and is a non-Specified Substance, which carries the heavier sanctioning treatment. S0 substances are Specified Substances but likewise prohibited at all times.
The List is written to catch what it does not name: S2 reaches "other substances with similar chemical structure or similar biological effect(s)", and S0 reaches any unapproved pharmacological substance. Absence from the table above is not a safe inference.
State law
We found no state statute that regulates research peptides as a class. The compounds above are not scheduled by the states any more than they are federally, and state controlled-substance acts generally track the federal schedules.
The one place state law does reach a peptide-adjacent molecule is growth hormone, folded into the anabolic steroid entries. Idaho is a clear example: Idaho Code 37-2709 sets out Schedule III, and subsection (f), headed "Anabolic steroids and human growth hormones", lists "Human growth hormones" among them. A state that has done this has made possession a state offense in a way federal law does not. Such provisions are not uniform, so a claim about any particular state should be checked against that state's code rather than a summary.
Beyond that, state law reaches this area indirectly, through professional licensing and the rules governing compounders — rules that bind practitioners and dispensers, not the sale of a characterized reagent to a laboratory.
What this means for a laboratory buyer
The legal picture is stable in its essentials even while the compounding lists move.
- Buying a characterized peptide as a laboratory reagent for in-vitro work is lawful.
- The material is not an approved drug, may not be offered for use in a person, and carries no FDA finding of safety or effectiveness.
- It is almost certainly not a controlled substance, and growth hormone is the exception worth knowing about.
- Imports are judged on whether the article appears to be an unapproved new drug, and the seller's own marketing is evidence on that question.
- Anti-doping status is independent of legality and is broader than most people expect.
What a buyer can act on is documentation. A lot number on the vial, a certificate of analysis tied to that lot, identity by mass spectrometry, purity by HPLC, and storage guidance are what make a reagent usable and a supplier checkable. More of that reasoning is in the quality and testing posts, and the storage and handling page covers keeping a lot intact once it arrives. A product page such as BPC-157 carries the identity data and the research-use statement together, which is the pairing to look for anywhere you buy.
For a legal opinion about your own situation, ask a lawyer. What this post offers is the primary sources, listed below, so the question can be checked rather than argued.
